While depleting MDSCs is a promising therapeutic strategy, several challenges remain:
- Heterogeneity: MDSCs are a heterogeneous population, making it difficult to target them specifically without affecting other immune cells. - Resistance Mechanisms: Tumors can develop resistance mechanisms that allow them to evade therapies targeting MDSCs. - Side Effects: Depleting MDSCs can sometimes lead to unintended side effects, including systemic immune activation that can result in autoimmunity.
